Non-Current Assets

Long-term marketable securities

Biogen Long-term marketable securities increased by 7.8% to $465.60M in Q1 2026 compared to the prior quarter. Over 5 years (FY 2020 to FY 2025), Long-term marketable securities shows a downward trend with a -11.0% CAGR.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2025
Last reportedQ1 2026

How to read this metric

An increase indicates a long-term capital preservation strategy, while a decrease suggests the liquidation of long-term investments to fund operations or debt repayment.

Detailed definition

This represents long-term investments in debt securities that the company intends to hold for more than one year. These...

Peer comparison

Used by mature companies with strong cash flows to manage long-term liquidity and investment returns.

Metric ID: non_current_assets_available_for_sale_securities_debt_se_908f76

Historical Data

14 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q4 '24Q4 '25Q1 '26
Value$915.10M$968.30M$892.00M$1.00B$1.10B$860.30M$705.70M$978.20M$1.21B$100.00K$0.00$0.00$431.90M$465.60M
QoQ Change+5.8%-7.9%+12.3%+10.1%-22.0%-18.0%+38.6%+23.5%-100.0%-100.0%+7.8%
YoY Change+20.5%-11.2%-20.9%-2.3%+9.5%-100.0%-100.0%
Range$0.00$1.21B
CAGR-18.8%
Avg YoY Growth-29.2%
Median YoY Growth-11.2%

Long-term marketable securities at Other Companies

Frequently Asked Questions

What is Biogen's long-term marketable securities?
Biogen (BIIB) reported long-term marketable securities of $465.60M in Q1 2026.
What is the long-term trend for Biogen's long-term marketable securities?
Over 5 years (2020 to 2025), Biogen's long-term marketable securities has grown at a -11.0% compound annual growth rate (CAGR), from $772.10M to $431.90M.
What does long-term marketable securities mean?
Long-term investments in debt securities held for interest income.